Nasdaq · Healthcare

Zentalis Pharmaceuticals, Inc. (ZNTL)

As-reported financials and recent SEC filings for Zentalis Pharmaceuticals, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

Net income

$-137.1M

Net margin

—

Diluted EPS

$-1.91

ROE

-63.4%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$0	$67.4M	$0	$0	—
Gross profit	—	—	—	—	—
Operating income	$-152.8M	$-191.2M	$-299.5M	$-227.3M	$-216.5M
Net income	$-137.1M	$-165.8M	$-292.2M	$-236.8M	$-158.7M
Diluted EPS	$-1.91	$-2.33	$-4.47	$-4.48	$-3.72

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-06-18

42026-06-18

42026-06-18

8-K2026-06-18

42026-06-18

42026-06-18

42026-05-27

32026-05-27

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on ZNTL

Search Zentalis Pharmaceuticals, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.